Welcome to our dedicated page for SRX Health Solutions SEC filings (Ticker: SRXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SRx Health Solutions, Inc. (NYSE American: SRXH) files a range of SEC documents that together outline its evolving strategy, capital structure and planned combination with EMJ Crypto Technologies Inc. (EMJX). On this page, investors can review current reports on Form 8-K, registration statements on Form S-1 and S-1/A, and other filings that describe material agreements, financing transactions and listing-status developments.
In its 8-K filings, the company discloses the Share Exchange and Asset Transfer Agreement to acquire EMJX, CCC Crypto Corp. and related intellectual property assets, including technology that uses artificial intelligence to predict outcomes from data sets. These reports also cover stockholder approvals for a future name change to EMJX, Inc. and a planned ticker change to EMJX, amendments to the Certificate of Incorporation to increase authorized common shares, and the designation of Series A Convertible Preferred Stock with detailed rights and conversion terms.
SRXH’s registration statements on Form S-1 and S-1/A provide additional information on private placements of Series A Convertible Preferred Stock and warrants, as well as an equity line of credit arrangement with Keystone Capital Partners, LLC. These documents explain how the company may raise capital through the issuance of equity and equity-linked securities, and they discuss risks associated with ownership of its securities. Filings also address NYSE American continued listing standards, including notices of non-compliance related to stockholders’ equity and the exchange’s acceptance of the company’s plan to regain compliance.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review them alongside AI-generated summaries that highlight key terms, structural features and risk considerations. This includes simplified explanations of complex documents such as 8-Ks describing material definitive agreements, S-1 registration statements detailing resale registrations and capital-raising arrangements, and governance-related amendments to the company’s charter and bylaws.
SRx Health Solutions, Inc. released a shareholder letter from EMJ Crypto Technologies founder Eric M. Jackson updating on their proposed merger and EMJX’s recent performance. EMJX deployed $18 million into its second-generation digital-asset treasury hedging strategy, earning a 5.69% return in March 2026 versus a 4.98% decline in the S&P 500, a 10.67% outperformance. Through mid-April, EMJX reports approximate gains of 3.5% in its hedging pool and 8% in long treasury holdings. The Company filed a Form S-4 registration statement for the merger, after which a regulatory review is expected before the transaction can close.
SRx Health Solutions, Inc. proposes an all-stock acquisition to buy EMJ Crypto Technologies Inc., CCC Crypto Corp. and related IP for an aggregate purchase price of approximately $55.00 million pursuant to a Share Exchange and Asset Transfer Agreement dated December 16, 2025 (amended March 11, 2026). The prospectus covers 418,250,951 shares of Common Stock that may be issued in the Transaction, based on an assumed price per share of $0.1315 (20‑Day VWAP as of April 10, 2026).
The Transferors are expected to hold approximately 46.43% of outstanding Common Stock after the Closing assuming 482,624,700 shares outstanding prior to the Closing. The Board unanimously approved the Transaction, received a fairness opinion from Hyperion Capital Inc., and stockholders holding 51.15% executed written consents approving the proposals. The Transaction is expected to close in Q2 2026, subject to customary conditions, regulatory approvals and NYSE American listing requirements.
SRx Health Solutions, Inc. Chief Executive Officer Kent Douglas Cunningham reported multiple equity awards that increase his ownership exposure, with no sales disclosed. On March 16, 2026, he received 247,522 Series B Warrants with an exercise price of $0.3182 per share, exercisable into the same number of common shares and expiring on March 16, 2029. On the same date he was also granted 63 shares of Series B Preferred Stock at $800 per share. Earlier awards include common stock grants of 231,193 shares on August 25, 2025 and 200,000 shares on December 3, 2025, both recorded as grants/awards rather than open-market purchases. One 44,464-share common stock position is held indirectly through Halo Spin-Out SPV Inc. The filing also reports a prior grant of 8,000 stock options with a $5.00 exercise price and 8,000 underlying common shares, along with several smaller common stock awards, all categorized as compensation-related acquisitions.
SRx Health Solutions, Inc. Chief Executive Officer Kent Douglas Cunningham filed an initial Form 3 reporting his ownership in the company. The filing lists 610,596 shares of common stock held directly, plus 44,464 common shares held indirectly through Halo Spin-Out SPV, Inc.
He also reports 63 shares of Series B Preferred Stock. In addition, he holds options covering 8,000 shares with a $5.0000 exercise price expiring on June 26, 2034, and Series B Warrants for 247,522 underlying shares with a $0.3182 exercise price expiring on March 16, 2029. This Form 3 records existing positions rather than new market transactions.
Conway Simon Alexander Malcolm reported acquisition or exercise transactions in this Form 4 filing.
SRx Health Solutions, Inc. director Conway Simon Alexander Malcolm reported two compensation-related stock awards of common shares. On August 25, 2025, he received 154,128 shares at a stated value of $0.40 per share, and on December 3, 2025, he received 630,000 shares at $0.39 per share. These are classified as grants or awards, not open‑market purchases. Following the most recent award, he directly holds 834,792 common shares.
SRx Health Solutions entered into a private placement Securities Purchase Agreement for up to 10,000 shares of Series B convertible preferred stock and accompanying warrants, for an aggregate purchase price of up to $8.0 million in one or more closings.
At the initial closing on March 16, 2026, investors purchased 5,660 Series B shares and 22,237,666 warrants for cash proceeds of approximately $4.528 million. Each Series B share has a stated value of $1,000, ranks senior to common stock (pari passu with Series A), and is convertible at a fixed price of $0.3182 per common share, subject to adjustments.
After stockholder approval, holders may elect alternative conversion prices tied to recent volume-weighted average prices, and the company may redeem all outstanding Series B at 125% of a defined conversion amount. The company agreed to register for resale common shares issuable upon conversion of the Series B and exercise of the warrants under a registration rights agreement.
SRx Health Solutions, Inc. files a prospectus supplement registering the resale of up to 187,552,665 shares of Common Stock by existing selling stockholders. The resale stock consists of multiple tranches including warrants, convertible-preferred-related shares, exchangeable Canadian shares, private placement shares, service‑provider shares and shares issued in a share exchange, and is offered by selling stockholders subject to applicable lock-up, vesting, beneficial ownership and stock exchange limitations described herein. The supplement attaches a Form 8-K describing a limited waiver and consent permitting a new preferred‑stock offering and related waivers among existing investors.
SRx Health Solutions, Inc. registers up to 2,506,893,959 shares of common stock for resale by Keystone Capital Partners, LLC.
The prospectus supplement states these shares are outstanding or issuable under a Common Share Purchase Agreement and that the Company will not receive proceeds from any resales by the selling stockholder; the Company may, at its discretion, sell shares to Keystone under the Purchase Agreement.
SRx Health Solutions, Inc. entered into limited waiver and consent agreements with certain existing investors to support a planned new financing. The company intends to sell a new series of convertible preferred stock, called Series B Preferred Stock, together with related warrants, to new accredited investors.
Under these waivers, existing note and Series A preferred investors agree to permit this new offering and give up their contractual rights to participate in it and in any later similar financings. Required holders of Series A Preferred Stock also consent so that the new Series B Preferred Stock may rank on an equal footing with the Series A Preferred Stock for dividends, distributions, and liquidation payments.
The filing also reminds investors that SRx previously raised capital through senior secured convertible notes with an original principal amount of $7.65 million and through a Series A preferred stock financing that generated approximately $15.23 million in proceeds along with related warrants.
SRx Health Solutions, Inc. files a prospectus supplement registering up to 187,552,665 shares of common stock for resale by named selling stockholders, consisting of PIPE‑related warrants and conversions, exchangeable shares, private placement shares, service provider shares and shares issued in a share exchange.
The resale is by the Selling Stockholders or their permitted transferees from time to time, subject to lock-up, vesting, beneficial‑ownership and exchange limitations described in the prospectus supplement. The supplement incorporates the Company’s Form 10‑Q for the quarter ended December 31, 2025, which discloses continuing operations (consumer pet products), discontinued SRx Canada operations, a net loss of $8.614 million for the quarter, and digital assets of $7.996 million at fair value as of December 31, 2025.